Group 1 - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. convened a meeting to discuss and approve changes to the use of special fundraising accounts and the establishment of new accounts [1][2] - The company agreed to change the purpose of existing fundraising accounts from various research projects to focus on "large model platform projects for peptide molecules" and "innovative drug research projects" [1][2] - New special fundraising accounts will be established by the company's subsidiaries for specific projects, ensuring that the funds are used solely for their intended purposes [1][2] Group 2 - The board approved an adjustment to the grant price of the 2025 restricted stock incentive plan from 22.78 yuan per share to 22.62 yuan per share due to the company's annual equity distribution [2][3] - This adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [2][3] - The voting results for the incentive plan adjustment showed unanimous support from the board members present [4]

Core Insights - Hanyu Pharmaceutical (300199) has recently conducted investor research, discussing the progress of the HY3003 new drug project, its layout in the innovative drug field, and overseas market expansion [1][2] Group 1: HY3003 New Drug Project - The HY3003 project has completed preclinical candidate compound screening and raw material process development, officially entering the raw material pilot scale-up phase, which validates the producibility of the molecular structure for subsequent IND application and clinical transformation [1] - HY3003 is a GLP-1R/GIPR/GCGR receptor agonist developed using AI peptide chip technology, aimed at weight loss indications [1] - The project employs a multi-formulation parallel development strategy, including weekly, ultra-long-acting monthly, and oral formulations, with the ultra-long-acting formulation designed to reduce dosing frequency and improve medication adherence [1] Group 2: siRNA and Other Drug Developments - The company is also developing siRNA drugs such as Inclisiran and Zilebesiran for treating high cholesterol and hypertension, as well as Pegcetacoplan for treating geographic atrophy [1] Group 3: Overseas Market Expansion - Currently, the company's raw materials are sold to over 20 countries and regions, with formulations licensed in over 90 countries and regions [2] - The company has signed cooperation agreements for the semaglutide injection (weekly formulation) and oral tablets in markets including China, Brazil, Egypt, Mexico, Eurasian Union, GCC member countries, and North Africa [2] - The company has completed the enrollment of all participants in the Phase III clinical trial for semaglutide injection as of January this year, with plans to submit for approval in China by 2026, followed by the US and other global markets [2] Group 4: Future Pipeline - Hanyu Pharmaceutical has a rich pipeline of peptide and small nucleic acid formulations, planning to launch no less than 20 formulations over the next 10 years, including innovative drugs, micro-innovative drugs, and ANDA [2]

Group 1 - The core viewpoint of the article highlights the collaboration between Shenzhen Hanyu Pharmaceutical Co., Ltd. and Zhuhai Carbon Cloud Peptide Pharmaceutical Technology Co., Ltd. on the HY3003 project, which has successfully completed preclinical candidate screening and raw material process development, entering the raw material pilot scale-up phase [2][3] - The HY3003 project is a GLP-1R/GIPR/GCGR tri-target receptor agonist for weight loss, utilizing AI peptide chip technology for high-throughput screening [2] - The project employs a parallel development strategy for multiple dosage forms, including weekly, ultra-long-acting monthly, and oral formulations [2] Group 2 - The management of Hanyu Pharmaceutical emphasizes the complementary strengths in technology and resources between the two companies, with Carbon Cloud Peptide possessing silicon-based peptide chip technology and AI algorithms, while Hanyu has extensive experience in peptide drug synthesis, purification, formulation development, and clinical translation [3] - A strategic cooperation was established in October 2024, followed by a joint development agreement in May 2025, aiming to incubate China's first tri-target peptide weight loss innovative drug [3] - Hanyu Pharmaceutical's Wuhan raw material production base passed FDA inspection with "zero defects" in November 2024, and the production line for Glatiramer Acetate Injection also successfully passed FDA inspection in 2025, with both products expected to launch in the U.S. market soon [3]

Core Viewpoint - Eli Lilly announced the official launch of Mounjaro® (tirzepatide injection multi-dose prefilled pen) in China, targeting adult patients with type 2 diabetes (T2DM) who have inadequate blood sugar control despite diet, exercise, and treatment with metformin and/or sulfonylureas [1] Group 1 - Mounjaro is the first and currently the only approved weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist for T2DM and long-term weight management [1]

Core Insights - Hanyu Pharmaceutical has entered the dosage maintenance phase for its Semaglutide injection project, with plans to apply for market approval in China by 2026 [1] Company Developments - The company is developing HY3003, a GLP-1R/GIPR/GCGR receptor agonist for weight loss, utilizing AI peptide chip technology for candidate selection [1] - Hanyu has completed preclinical candidate screening and raw material process development, now moving into the raw material pilot scale-up phase [1] - In addition to the weight loss drug, the company is also working on an innovative drug, HY3000 nasal spray, aimed at preventing coronavirus infections, which is currently in Phase III clinical trials [1] Collaborations and Innovations - Hanyu is collaborating with China National Pharmaceutical Group on the research and commercialization of Cannabidiol (CBD) innovative drugs, integrating peptide and small nucleic acid drug technologies [1] - The company has completed enrollment of all participants in the Phase III clinical trial for Semaglutide injection as of January this year and is currently in the follow-up phase [1]

证券研究报告 | 2025年06月09日 金融工程日报 沪指盘中回归 3400 点，创新药概念活跃领涨 市场表现：今日(20250609) 大部分指数处于上涨状态，规模指数中中证 2000 指数表现较好，板块指数中科创 100 指数表现较好，风格指数中中证 500 成 长指数表现较好。医药、综合、纺织服装、国防军工、农林牧渔行业表现较 好，食品饮料、家电、汽车、建筑、交通运输行业表现较差。多肽药、CRO、 减肥药、黄酒、新冠特效药等概念表现较好，黄金精选、高速公路精选、吉 利集团、中国铁总、供销社等概念表现较差。 市场情绪：今日市场情绪较为高涨，收盘时有 90 只股票涨停，有 4 只股票 跌停。昨日涨停股票今日收盘收益为 3.14%，昨日跌停股票今日收盘收益为 -1.86%。今日封板率 66%，较前日提升 5%，连板率 32%，较前日提升 12%。 市场资金流向：截至 20250606 两融余额为 18086 亿元，其中融资余额 17964 亿元，融券余额 122 亿元。两融余额占流通市值比重为 2.3%，两融交易占市 场成交额比重为 8.3%。 折溢价：20250606 当日 ETF 溢价较多的是信创 ET ...

整理 | GLP1减重宝典内容团队 按地区分，2024年上半年，泰德医药来自美国的收入达1.22亿元，同比大增165%，美国市场收入占公司营收总额的比例由去年同期的28.2%增 至61.8%。同时，日本地区收入占比则由39.5%锐减至1.3%。 产能扩张：中美双线布局，瞄准GLP-1市场 为满足日益增长的市场需求，泰德医药正在积极扩张产能。在中国，公司在钱塘园区建有建筑面积超过15,000平方米的cGMP厂房，拥有19条多 肽合成生产线和16条纯化生产线，2023年API年产能为500千克，利用率为68.2%。此外，公司计划在未来两至三年内在中国建设或收购新的生 产园区，预计将使年产能提高约2,000千克。 2025年6月3日，泰德医药（浙江）股份有限公司（Medtide Inc.）顺利通过港交所聆讯，迈出上市关键一步。作为全球第三大专注于多肽的 CRDMO（合同研究、开发与生产）企业，泰德医药正借助GLP-1类药物的热潮，寻求在资本市场的新突破。 全球多肽CRDMO格局：泰德医药位列第三，市场份额1.5% 根据弗若斯特沙利文的数据，按2023年销售收入计，泰德医药在全球专注于多肽的CRDMO企业中排名第三， ...

证券研究报告 | 公司研究 gszqdatemark 2025 05 22 年 月 日 阳光诺和（688621.SH） 收购朗研加码创新，"研发服务+管线培育+新质产业链"三位一体 拟收购朗研 100%股权，助力创新转型加速。公司拟通过发行股份及可转 换公司债券方式购买江苏朗研生命科技控股有限公司 100%股权，并向不 超过 35 名特定投资者发行股份募集配套资金。收购朗研生命有望提高行 业竞争力和盈利能力，完善战略布局，一方面，公司能够实现自主研发产 品的孵化和实施，充分发挥公司研发优势和朗研生命的生产销售优势，促 进研发品种落地以及朗研生命产能释放，形成公司新的盈利增长点。另一 方面，公司将增加医药工业板块业务，实现"CRO+创新研发+医药工业" 的产业布局。未来，医药工业板块将成为公司主营业务的重要组成部分， 进一步提高上市公司盈利能力及抗风险能力，促进上市公司的可持续发 展。 发布股权激励草案，深度绑定核心骨干。公司本次激励计划拟授予的限制 性股票 272.1783 万股，占本激励计划草案公告时公司股本总额 11,200 万 股的 2.43%，授予价格为 22.78 元/股，激励对象 127 人，包括 ...

Investment Rating - The report assigns a "Buy" rating for the company with a target price of HKD 18.77 per share, based on a current price of HKD 13.2 [7]. Core Views - The company is expected to achieve stable growth in its insulin and animal health businesses, supported by a strong pipeline of innovative drugs, particularly in the weight loss sector with UBT251 showing promising clinical results [2][4][6][7]. - The overall revenue forecast for the company from 2025 to 2027 is projected at HKD 145.24 billion, HKD 139.87 billion, and HKD 145.80 billion, with a net profit of HKD 29.07 billion, HKD 25.57 billion, and HKD 27.62 billion respectively [6][7]. Summary by Sections 1. Antibiotics - The company has established itself as a leader in the penicillin industry with a market share of approximately 50% in both penicillin industrial salt and 6-APA [5]. - The antibiotic business is expected to maintain stability due to the overall industry outlook and the company's integrated supply chain advantages [5][7]. 2. Weight Loss: UBT251 - UBT251 has been licensed to Novo Nordisk, with an upfront payment of USD 200 million and potential milestone payments of up to USD 1.8 billion, along with tiered royalties based on net sales [2]. - Clinical trial results for UBT251 show a weight reduction of 15.1% from baseline after 12 weeks, surpassing the performance of similar products [2]. 3. Insulin - The company has successfully bid for all six procurement groups in the national insulin procurement process, with all products selected classified as A-level [3]. - The stable procurement policy is expected to support the growth of the insulin business [3]. 4. Animal Health - The company anticipates launching 19 animal health products starting in 2025, with over 10 products expected to be approved annually from 2026 to 2028 [4]. - The expansion into the pet market is expected to drive accelerated growth in the animal health segment [4]. 5. Financial Forecast and Valuation - The company is valued using a comparable company valuation method, with a target market capitalization of HKD 341.02 billion [6][7]. - The main business is assigned a PE ratio of 6x for 2025, while the innovative drug segment is assigned a PE ratio of 20x [7].

拐点已现，积极配置 ——CXO 2024&2025Q1业绩综述 行业评级：看好 2025年05月14日 | 分析师 | 郭双喜 | 王帅 | | --- | --- | --- | | 邮箱 | guoshuangxi@stocke.com.cn | wangshuai@stocke.com.cn | | 电话 | 19801116960 | 13548094491 | | 证书编号 | S1230521110002 | S1230523060003 | 1 1、股价复盘： 2、财务分析： ➢ 本土：业绩、订单&AI是主线。 2024.12.31至2025.04.30，医疗研发外包指数上涨0.82%，跑赢医药生物（申 万）指数0.64pct，其中药明生物（+31.55%） 、药明合联（+23.65%） 、泓博医药（+16.11%） 、凯莱英 （+7.77%）、药明康德（+7.50%）表现较好。 95% ➢ 海外：业绩分化，CDMO更强劲。2024.12.31至2025.04.30，Lonza及LABCORP领涨。从指引看跨国CXO公 司只有Lonza对CDMO业务（胶囊与健康原料CHI以外业务）2025年指引 ...